Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240,501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, André F. Musolino A, et al. Among authors: zhang y. Breast Cancer Res. 2017 Feb 10;19(1):18. doi: 10.1186/s13058-017-0807-8. Breast Cancer Res. 2017. PMID: 28183331 Free PMC article. Clinical Trial.
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. André F, et al. Among authors: zhang y. Clin Cancer Res. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. Epub 2013 May 8. Clin Cancer Res. 2013. PMID: 23658459 Clinical Trial.
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. Korde N, et al. Among authors: zhang y. JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010. JAMA Oncol. 2015. PMID: 26181891 Free PMC article. Clinical Trial.
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, Emanuel M, Petrosyan A, Bhutani M, Calvo KR, Dulau-Florea A, Kwok M, Lee MJ, Lee S, Lindenberg L, Mailankody S, Manasanch E, Maric I, Mena E, Patel N, Tageja N, Trepel JB, Turkbey B, Wang HW, Wang W, Yuan C, Zhang Y, Braylan R, Choyke P, Stetler-Stevenson M, Steinberg SM, Figg WD Sr, Roschewski M, Landgren O. Kazandjian D, et al. Among authors: zhang y. JAMA Oncol. 2021 Nov 1;7(11):1678-1685. doi: 10.1001/jamaoncol.2021.3971. JAMA Oncol. 2021. PMID: 34529025 Free PMC article. Clinical Trial.
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.
Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O. Mailankody S, et al. Among authors: zhang y. Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10. Blood Adv. 2017. PMID: 29296837 Free PMC article.
240,501 results
You have reached the last available page of results. Please see the User Guide for more information.